Alzheimer’s Disease: A New Treatment
Alzheimer’s disease is considered incurable. In the last 10 years 244 drugs have been tried. None have worked. Four drugs are currently licensed for Alzheimer’s but none stop the relentless decline which is a hallmark of this disease. It is widely believed that drug companies have stopped researching Alzheimer’s as they believe there is little hope of finding an effective drug. However in 2014 a paper was published that showed that, in 9 out of 10 patients with Alzheimer’s disease, there was reversal of cognitive decline. This had never happened before.
The Breseden Protocol
This paper was published by research neurologist Dr Dale Breseden’s team at UCLA. They had discovered the key biochemical change in Alzheimer’s disease (see below). Since then the Breseden protocol (called ReCODE) has been used to successfully treat 200 people in 7 countries.
The Biochemistry of Alzheimer’s Disease
Alzheimer’s disease occurs when the rate of destruction of neurons is greater than the rate of formation of new neurons. The key to Alzheimer’s is a molecule that sits on the neuron receptor called APP (amyloid precursor protein). And it is the way APP breaks down that determines whether Alzheimer’s develops or not. It can either break down into two nerve nourishing substances (creating new nerves and new synapses) or into a quartet of nerve-damaging substances (which destroy nerves and cause amyloid formation). If the latter occurs then Alzheimer’s develops.
They went on to discover that the way APP breaks down is dependent on whether there is enough essential substances available to the nerve (which include netrin-1,brain-derived neurotrophic factor, BNDF, and other key brain nutrients) which promote nerve formation and whether there is an excess of harmful substances (which include amyloid and biotoxins) which promote nerve destruction. Of critical importance they found that by controlling these factors that it was possible to tip the balance away from nerve destruction back to nerve creation.
In all they discovered 36 factors which affect the control of this key biochemical change. The first patient to go on the protocol was able to reverse her cognitive decline by altering just 12 of these.
Why have I not heard of this?
Alzheimer’s disease has a massive impact on people and has an equally massive impact on the NHS budget and, like diabetes, could bankrupt the NHS if numbers continues to increase at the present rate. Surely any discovery should make people sit up and take notice?
Sadly this hasn’t been the case. Dr Breseden initially thought he might discover a drug to halt this process but soon realised this would not be possible and there would be no one-size-fits-all remedy. It could only be fixed by altering the many risk factors which influence the breakdown of APP. These vary in different Alzheimer’s patients. He applied to have his protocol tested but was turned down and told it was too complex. (This complexity is the very reason why no successful drugs have yet been found).
However, scientifically, it is well-recognised that if a disease is universally fatal a control group is unnecessary. Success itself is proof of effectiveness. As Breseden notes that everyone knows a cancer survivor but no one has heard of an Alzheimer’s survivor. Even with a handful of successful cases the statistical odds of it being a chance happening rapidly reach millions to one against. (It only took 4 cases to prove penicillin was effective).
In addition to this Dr Breseden has shown that key features of the disease, like shrinkage of the hippocampus (the main area of the brain affected in Alzheimer’s), reverse when the protocol is used.
Types of Alzheimer’s
Dr Breseden’s team discovered 3 types of Alzheimer’s. One they called inflammatory; it was often related to the ApoE4 gene and responded well to the protocol. The second was called atrophic; it was again often related to the ApoE4 gene and was caused by lack of essential brain nutrients and hormones (which decrease with age). This again responded to the protocol but took longer. The third was called toxic and was unrelated to the ApoE4 gene and was caused by environmental threats and biotoxins. It was the hardest type to treat.
How does the Protocol work?
The first stem involves measuring all 36 of the factors which affect Alzheimer’s risk, usually with blood tests. He found that typically 25 are low or subnormal and need to be corrected. (Unfortunately many of these tests are not available on the NHS). The second step involves returning all these factors to optimal levels. To do this requires lifestyle changes and specific nutrients, hormones etc.
To give one example: in the inflammatory type of Alzheimer’s there is nearly always a condition called metabolic syndrome which causes an excess of insulin. In this condition the enzyme that breaks down insulin is so overworked that none is left for the breakdown of amyloid in the brain, making nerve destruction more likely. The answer to this is to change the diet away from sugar and refined carbohydrates and have at least a 12 hr gap between eating at night and breakfast. However this is just one of the 36 factors.
What should I do if I want to try the protocol?
There are a number of doctors in the country who use this protocol and have been trained by Dr Breseden. Unfortunately this programme is not available on the NHS (even though it could save the NHS a lot of money). It will not work in severe Alzheimer’s because by then nerve destruction is thought to be irreversible.
It is important to mention there are scams. There have been imitations of the Breseden protocol so it is important to check it is the real thing.
How quickly does it work?
It typically takes 3 to 6 months for these brain changes to reverse. The disease can relapse within a few weeks if the protocol is stopped.
Dr Breseden has written a book called The End of Alzheimer’s: the First Programme to Prevent and Reverse the Cognitive Decline of Dementia which describes his protocol in much more detail. There is also a website called ApoE4.info for people with this gene or with Alzheimer’s.